Polyneuron: Polyneuron and University of Basel Awarded Grant of CHF 1.2M to Advance Novel Treatments to Support ABO-Incompatible Transplants

Polyneuron Pharmaceuticals AG, a clinical-stage developer of a new class of antigen-specific polymers for the treatment of patients with serious autoimmune diseases, announced that the company and collaborators at the University of Basel have received a grant from the Swiss Innovation Agency Innosuisse to support a project valued at CHF 1.2 million.